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Ultrasound-guided synovial biopsy is a safe, well-tolerated, and effective method to
collect good-quality synovial tissue from all types of joints for clinical and research
purposes. Although synovial biopsy cannot be used to distinguish between types
of inflammatory rheumatic disease, analysis of synovial tissue has led to remarkable
advances in the understanding of the pathobiology of rheumatoid arthritis and other
inflammatory rheumatic diseases. Synovitis is the hallmark of these diseases; hence,
accessing the core of the pathological process, synovial tissue, provides an opportunity
to gather information with potential diagnostic and prognostic utility.
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INTRODUCTION
This review aims to gather, in a single source, the most comprehensive information on ultrasound-
guided synovial biopsy (USGSB), including the unmet needs of the method.
USGSB is a method for retrieving synovial membrane samples using ultrasonography for
guidance. The main advantages of USGSB are that it is well-tolerated by patients; is accessible;
can feasibly be performed in large and small joints, as well as bursae and tendon sheaths; and has
a low incidence of adverse events. USGSB uses ultrasound to visualize the location of synovial
hypertrophy and is simple to perform after adequate training, suitable for serial procedures, and
comparable to arthroscopy (which is considered the gold standard for obtaining synovial samples,
based on clinical trial data) in terms of sample quality, but is less invasive, is cheaper, and does
not require ionizing radiation, unlike fluoroscopy-guided biopsies (1–5). The main disadvantages
of USGSB, relative to arthroscopic biopsy, are the limited tissue quantity obtained and lack of
direct vision. Moreover, when using USGSB, the synovial tissue retrieved depends on the degree
of synovitis and requires musculoskeletal and ultrasound guidance skills. Major contraindications
to USGSB are systemic or skin infection, coagulation disorders, or anticoagulant therapy, as well as
a non-collaborating patient.
In this review, we address the following questions: Why are synovial biopsies conducted? How
are synovial biopsies conducted? What data do synovial biopsies provide? andWhat are the unmet
needs related to synovial biopsy?
WHY ARE SYNOVIAL BIOPSIES CONDUCTED?
Synovial biopsies are conducted for clinical reasons or research purposes (6, 7). In the clinical
setting, formal indication for synovial biopsy occurs in cases of monoarthritis for which all other
auxiliary diagnostic tests, including synovial fluid examination, are insufficient for diagnosis.
Clinical biopsies are performed to exclude infection or because diagnostic clarification is required;
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for example, to identify whether synovitis has a non-
inflammatory or inflammatory cause. Tumors cause non-
inflammatory synovitis, while crystal-related arthropathies and
granulomatous and non-granulomatous diseases are responsible
for inflammatory synovitis. Crystal-related arthropathies are
due to sodium monourate, calcium pyrophosphate, or basic
calcium phosphate deposition diseases. Granulomatous synovitis
can be related to infection (tuberculosis, brucellosis, fungal
infections), immunological (Crohn’s disease, erythema nodosum,
sarcoidosis), metabolic, and storage diseases, or to a reaction
to a foreign body. Non-granulomatous synovitis may be due to
septic arthritis, low-grade synovitis (post-traumatic, mechanical,
osteoarthritis, or haemochromatosis-related synovitis), or high-
grade synovitis (rheumatic inflammatory diseases, such as diffuse
connective tissue diseases or spondyloarthritis) (Figure 1).
Bacterial and fungal diseases can be identified by detection of
broad-range 16S and 18S ribosomal RNA in synovial tissue by
polymerase chain reaction, which is valuable for the diagnosis of
infection by these agents (4).
Synovial biopsies are conducted for research purposes in
the context of the study of inflammatory rheumatic disease
pathogenesis, early diagnosis, new drugs (through recognition of
novel therapeutic targets), identification of biomarkers of disease
progression, or advance precision medicine (8, 9). Nevertheless,
synovial biopsy is not yet sufficiently discriminative to allow
distinction between types of arthritis (10).
HOW ARE SYNOVIAL BIOPSIES
CONDUCTED?
Comparison of Synovial Biopsy
Approaches
Synovial biopsies can be achieved in the context of surgery
(arthrotomies, arthroplasties) fluoroscopic or arthroscopic
guided, or conducted as a blind needle- or ultrasound-guided
procedure. USGSB is conducted as either a portal + forceps
biopsy (PFB) or a guillotine-type semiautomatic needle biopsy
(NB). PFB can be rigid or flexible, while NB can be conducted
with or without a coaxial; coaxial is helpful when there is a long
pathway to deep-seated joints, or when the needle passes near
neurovascular structures (Figure 2). USGSB clearly has the most
well-balanced profile among synovial biopsy approaches, when
cost, technical simplicity, patient acceptability, synovial sampling
success rate, suitability for large and small joints, and suitability
for serial biopsies are considered (2). Of interest, synovial tissue
quality is maintained and clinical and ultrasound evaluations do
not change when repeat USGSB is necessary for the same joint
(2, 7, 11, 12). Blind needle- and fluoroscopy-guided biopsies are
more difficult to conduct in small joints and joints without active
synovitis and have a lower success rate for obtaining synovial
samples than other methods (2, 5). Cost and technical simplicity
favor blind needle biopsy, while suitability for serial biopsies and
biopsies in small joints favor USGSB, particularly NB (2, 13–15).
The major differences between the two types of USGSB are that
PFB requires an autoclave for equipment sterilization, one guide,
larger ports, and dual operators and is more time consuming
(10), while NB uses disposable material, can be easily achieved
by a single operator, and is most appropriate for finger, toe, and
wrist joints (the joints most frequently affected in rheumatoid
arthritis); however, the choice between PFB and NB depends
primarily on operator preference and experience.
Compared with arthroscopic biopsy, USGSB is less invasive
and can be conducted in both large and small joints (6).
Arthroscopic biopsy allows direct visualization of synovial
membranes but is more costly, is performed in only a few
specialized centers, requires two operators and a dedicated
environment (an operating theater or equivalent), and is not
viable for small joints (1, 2, 13, 14).
There are no differences between arthroscopic biopsy, PFB,
and NB in terms of synovial sample quality, adverse events, or
reported patient outcomes. Also, synovial pathotype and degree
of inflammatory infiltrate are not influenced by the method used
to retrieve synovial samples (2, 3).
Synovitis grade (synovial thickness) on pre-biopsy grayscale
ultrasound scan is the best predictor of successful USGSB, in
terms of synovial sampling and grading. Kelly et al. proposed
a joint selection hierarchy for biopsy, based on joint size and
synovitis grade on grayscale ultrasound (16). According to this
hierarchy, the first choice should be a medium or large joint,
with grade 3 synovial thickening, followed by a joint of any size
with synovitis grade ≥ 2, a medium or large joint with synovitis
grade ≥ 1, and finally, a small joint with any degree of synovitis.
Although not a contraindication, performing a synovial biopsy in
a grade 1 synovitis is technically harder to accomplish, especially
in the hands of a non-experienced operator.
The USGSB Procedure
In any rheumatological center, several steps should be
implemented to adequately perform USGSB. In the author’s
department, the first step is a checklist, which includes patient
reception; exclusion of procedure contraindications; written
informed consent; clinical data collection, including biometric
items, tender joint count, swollen joint count, erythrocyte
sedimentation rate, and C-reactive protein levels; patient- and
physician-scored global activity (visual analog scale; VAS);
ongoing treatment; and factors related to the joint to be biopsied,
including VAS scores for pain, stiffness, and swollenness in the
previous week.
The biopsy procedure should be carried out in a theater or
clean procedure room, providing sufficient expanse for a sterile
trolley, a bed, and an ultrasound machine. Most USGSBs are
best performed with the patient in the supine position and
the physician seated. Before the procedure, a brief ultrasound
examination of the joint to be biopsied is performed to plan
the most adequate needle path, in order to avoid tendinous
and neurovascular structures, and synovitis grade is determined,
according to grayscale and power Doppler.
A support table, with all required equipment and materials,
is prepared and a sterile technique implemented. Sterile gel or
chlorhexidine solution must be used as a contact medium. An in-
plane approach, trying to keep the needle as parallel as possible
to the probe, is the best option. Then, each USGSB procedure
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FIGURE 1 | Why are synovial biopsies conducted?
FIGURE 2 | How are synovial biopsies conducted?
follows a similar routine with fluid aspirated (if present) and 1–
5ml of local anesthetic injected into the soft tissues up to the joint
capsule, under US guidance. A further 2–5ml of 1% lidocaine
is instilled into small joints, 10–15ml for large joints. For large
joints such the knee, hip, or shoulder, a suitable coaxial outer
needle may be used in addition to the 14- or 16-G biopsy needle,
to facilitate repeated needle entry over a long path. For small
and intermediate joints, a 16-G, throw-length 10-mm biopsy
needle is used, without a coaxial sheath. US imaging is used to
guide the needle to an appropriate predetermined biopsy site.
After the procedure, compression of the entry site is followed by
the application of a small adhesive dressing. Some of the steps
involved are illustrated in Figures 3–8.
When the procedure is completed, the patient is asked to grade
his/her tolerance for the intervention. In our experience with NB,
the time spent for the whole procedure is<70min, of whichmore
than half is spent in the pre-procedure steps, with the biopsy
itself usually lasting < 35min. Pre-procedure steps include the
checklist (around 10min); brief ultrasound examination (5min);
and operator, material, and patient preparation (20min = 5 +
10 + 5min, respectively). Five to 14 days post-biopsy, patients
are asked to grade their discomfort during the procedure and
whether they took over the counter analgesics. Besides, they are
requested to grade the pain, stiffness, and swollenness in the
biopsied joint over the previous 3–4 days and their willingness
to repeat the procedure, if needed. Any adverse events that may
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FIGURE 3 | Materials required for USGSB.
FIGURE 4 | Field and probe cable protection.
have occurred are recorded and ultrasound examination of the
biopsied joint performed.
Synovial Sample Collection and Processing
Synovial sample collection is driven by the procedure goal—
clinical or research. For clinical purposes, ≥6 fragments
are sent for paraffin embedding and ≥5 for microbiology.
Fragments sent for paraffin embedding are then sectioned into
thin slices using a microtome and sent for histopathological
analysis, following staining with hematoxylin–eosin. For research
purposes, ≥6 fragments are sent for paraffin or optimal cutting
temperature cryoprotective compound embedding. After thin
sections are cut, samples are analyzed by immunohistochemistry
or immunofluorescence for cell-type identification, according to
the research goal. We also store ≥ 6 fragments in RNALater,
which is a substance that counteracts RNA degradation by
RNAases, for subsequent transcriptome analysis (7). The final
number of samples collected inevitably depends on and reflects
the research goal, patient tolerability, and time available (10).
FIGURE 5 | Local anesthesia.
FIGURE 6 | Insertion of biopsy needle.
The European Synovitis Study Group (ESSG) recommends as
quality criteria that biopsy size should be >2.5 mm2 and that
the synovial lining layer, as well as the overall morphology of the
tissue, must be preserved (17). The same group recommends that
synovitis should be quantified; one of the most popular scoring
systems for that purpose is Krenn’s score, which assesses three
features of synovitis: hyperplasia of the lining cell layer, stromal
cell density, and intensity of inflammatory infiltrate. Krenn’s
score can range from 0 to 9, as follows: 0–1, no; 2–4, low-grade;
and 5–9, high-grade synovitis (18). The ESSG also recommends
that the synovial pathotype, as well as the presence of ectopic
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FIGURE 7 | Biopsy needle inside the joint.
FIGURE 8 | Synovial samples.
lymphoid follicles, should be described (17). Other authors have
recommended six as the minimum number of samples to collect
for immunohistochemistry, to reduce T cell variability; however,
the minimum number of samples for other cell types is less well-
established. For macrophages, it depends on the goals pursued
by the research (6). Other measures of synovial tissue quality
include the number or percentage of synovial fragments and
gradable synovial fragments, the total area of gradable synovial
tissue, the area of gradable tissue by biopsy sample, and the RNA
integrity number (RIN) (2); RIN ranges from 1 to 10, where
samples from synovial tissue with values > 3 are considered
adequate for subsequent transcriptomic analysis (2), molecular
analysis, gene expression profiling, or gene sequencing methods
(e.g., next-generation sequencing) (5). The capacity of USGSB to
retrieve sufficient RNA is remarkable, even from small joints with
minimal synovitis.
WHAT DATA DO SYNOVIAL BIOPSIES
PROVIDE?
Healthy Synovial Membrane
Synovial tissue analysis is a fundamental tool for investigating
arthritis pathobiology and searching for biomarkers of treatment
response in basic and translational research, and is a useful
method in routine clinical practice (11). To better understand
the value of USGSB, it is crucial to have adequate knowledge
of the “normal” synovial membrane or synovium, which is
an ectoderm-derived structure that coats the inner surface of
diarthrodial joints. The synovium has folds or villi, which provide
non-restrictive motion and an augmented absorptive area; may
be discontinuous, resulting in occasional bare areas of cartilage
or bone; and contains two parts, the intimal lining layer, which
is in contact with the joint cavity, and the stroma or sublining
layer, with no basal lamina or membrane between them. The
microanatomy of the normal synovial membrane can be divided
into three types, fibrous, areolar, and adipose, according to the
structure and contents of the sublining layer, with the areolar
subtype the most typical and ubiquitous, the adipose subtype
primarily found in fat pads, and the fibrous subtype found in
finger and toe joints (19).
The normal synovial membrane has several functions: (1)
it allows the movement of adjacent relatively non-deformable
structures; (2) it maintains an intact non-adherent tissue surface;
(3) it controls synovial fluid volume and composition; (4) it
lubricates cartilage; (5) it nourishes chondrocytes; and (6) it
absorbs debris and metabolic waste products (19, 20).
Normal intima is formed by one or two layers of synoviocytes.
These can be (1) type A synoviocytes, which are macrophage-
like and derived from blood monocytes via subintimal venules,
or (2) type B synoviocytes, which are the most abundant, locally
derived fibroblast-like synoviocytes of mesenchymal origin. The
usual pattern found in the lining layer is a first row of type A
synoviocytes, in close contact with the joint cavity, below which
there is a row of type B synoviocytes (19). Type A synoviocytes
are capable of phagocytosis and pinocytosis and have numerous
micro-filopodia and prominent Golgi apparatus. Type B
synoviocytes have prominent rough endoplasmic reticulum
organelles and synthesize hyaluronan, fibronectin, laminin,
collagens, catabolin, lubricin, “superficial zone protein,” neutral
proteinases, collagenase, and gelatinase. Type B synoviocytes
also express several adhesion molecules, including vascular
cell adhesion molecule 1 (VCAM-1), intercellular adhesion
molecule-1 (ICAM-1), β1 integrins, and the surface markers,
CD44 and CD55. The extracellular connective tissue matrix
of the lining layer includes a fine fibrillary net of type I,
III, IV, V, and VI collagens, as well as variable amounts
of hyaluronan, laminin, fibronectin, chondroitin-6-sulfate-rich
proteoglycan, and fibrillin-1 microfibrils (10, 19, 20). Large
amounts of hyaluronan are present in the lining layer, as
well as in the part of the sublining layer that is closer to
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the lining layer, while there is no hyaluronan deeper in the
subintimal layer.
The normal sublining layer is relatively acellular and contains
some blood and lymphatic vessels. Fibroblasts and adipocytes
are the dominant cell types in the sublining layer, while a few
macrophages, B lymphocytes, plasma cells, CD3+, CD4+, and
CD8+ T lymphocytes, granzyme B-positive cells, interdigitating
antigen-presenting dendritic cells, and mast cells may also be
found, but in small numbers (19). The part of the sublining
layer closer to the lining layer also has a row, two to three cells
thick, beneath which there are capillaries, with a deeper plexus of
small arterioles and venules, with lymphatic vessels found deepest
(furthest from the lining layer) in the sublining layer (19). A
rich network of sympathetic and sensory nerves is present in the
synovium, usually associated with blood vessels, and extending
into the intimal layer. These nerves are myelinated and terminate
close to blood vessels, whose vascular tone they regulate.
Sensory nerves respond to proprioception and pain via large
myelinated nerve fibers or myelinated fibers with unmyelinated
free endings (nociceptors), or via small unmyelinated fibers.
Synovium nociceptors are reactive to neuropeptides, including
vasoactive intestinal peptide, calcitonin gene-related peptide, and
substance P (20). The sublining layer contains many elastic
fibers, providing tautness to this part of the synovium, which
is mainly composed of loose connective tissue, but contains
other constituents, including laminin, fibronectin, chondroitin-
6-sulfate-rich proteoglycans, and type I, III, IV, V, and VI
collagens (19, 21).
Synovial macrophages are CD163+, CD68+, CD11b+, and
CD14+; however, subintimal macrophages are strongly positive
for CD14, while intimal macrophages are only weakly positive.
There are other differences betweenmarkers expressed by intimal
and subintimal macrophages in healthy synovium: intimal
macrophages express strong non-specific esterase (NSE) activity
and the immunoglobulin receptor, FcgRIIIa, while subintimal
macrophages are weakly positive for NSE activity and express
the immunoglobulin receptor, FcgRI, with low or absent levels
of FcgRIIIa (19, 21).
Regarding cytokine production in normal synovium, although
very small amounts of pro-inflammatory cytokines, such as
interleukin-1β (IL1β), interleukin 6 (IL-6), and tumor necrosis
factor-alpha (TNF) are generated, levels are much lower than
those present in any type of synovitis. In contrast, levels of
IL1β receptor antagonist and osteoprotegerin, which inhibits
receptor activator of NF kappa B ligand (RANKL), in the normal
synovium far exceed those of the molecules they inhibit (19).
Synovial Pathology
In the context of clinical arthritis, analysis of synovial
tissue allows the identification of lymphocytic aggregates
that can produce local autoantibodies, potential biomarkers
differentiating rheumatoid arthritis (RA) from other forms of
early arthritis, distinct fibroblast cell types in involved or non-
involved arthritic joints, and decreasedmacrophage numbers as a
surrogatemarker of treatment response (1, 13). Indeed, decreased
number of macrophages (CD45+ or CD68+) in the synovial
sublining is the most reproducible and validated biomarker
of treatment efficacy in RA, and more reliable than disease
activity score 28 (DAS28) (12, 13, 22). In contrast, macrophage
infiltrate density correlates with progressive structural damage.
In addition to macrophages, B cell aggregates and mast cells are
also associated with severe disease in RA (23–28). Other potential
biomarkers in synovial tissue include different populations of
lymphocytes and lymphocyte aggregates, cytokines, chemokines,
S100 proteins, adhesion molecules, mediators, and degradation
products from bone, cartilage, and synovial membrane, various
antigens and antibodies, and genes involved in the regulation
of cell division and immune responses (9). The degree of
infiltration and aggregation of lymphocytes in synovial tissue,
the number of CD68+ macrophages in the sublining, and
global synovial inflammation scores, as well as levels of pro-
inflammatory cytokines, chemokines, and catabolic enzymes in
the synovium, all correlate with disease activity, erosive burden,
and radiographic progression. Flow cytometry, bulk-RNA
sequencing, and single-cell technologies (mass cytometry and
single-cell RNA sequencing), used in judicious sequence, have
facilitated high-resolution identification of disease-associated
cell subsets in human tissues. These technologies have enabled
the identification of four distinct fibroblast populations in the
synovium (three in the sublining layer and one in the lining
layer); four populations of monocytes; six of T cells (three CD4+
and three CD8+); and four of B cells (naïve B cells, memory
B cells, autoimmune-associated B cells, and plasmablasts) (29).
Taken together, these data demonstrate that analysis of synovial
tissue is an important tool with prognostic value, in terms of
phenotypic variability, disease activity, and disease severity (21).
The Doppler signal in RA correlates with hyperplasia of
the synovial lining, lymphoid and macrophage infiltration of
the sublining, angiogenesis, and lympho-myeloid pathotype (9,
30–32). Both the lining and sublining layers of the synovium
exhibit typical features during rheumatoid synovitis. In the
lining layer, rheumatoid synovitis manifests as hyperplasia,
due to synoviocyte proliferation, with a dramatic increase of
type A synoviocytes, which may account for up to 80% of
the intimal layer, and mononuclear cell infiltration, caused by
recruitment of bone marrow-derived monocytes, reaching up
to 12 cells in thickness; these two types of cells are important
sources of cytokines, chemokines, matrix-degrading enzymes,
adhesion molecules, and osteoclastic and angiogenic factors.
Further, increased fibronectin content, with resultant fibrin
deposition in the superficial layer of the inflamed synovium and
expansion of the lining layer and increased metabolic demands,
is observed, but with few blood vessels in the vicinity, suggesting
relative hypoxia, a potent stimulus to produce VEGF and other
angiogenic mediators.
In the sublining layer, rheumatoid synovitis causes stromal
proliferation, with pronounced infiltration by monocytes,
macrophages (mainly pro-inflammatory M1 macrophages,
monocyte-derived), T cells (mainly, but not limited to, CD4+
Th1 and Th17, and CD45 RO+ T cells), B cells and plasma
cells (mainly antibody-producing, but also chemokine and
cytokine producers), dendritic cells (myeloid and plasmacytoid
dendritic cells, which are antigen-presenting cells, producers
of inflammatory mediators and cytokines, and possibly also
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involved in local autoantibody production), NK cells (a source
of IL-22, and mediator of fibroblast proliferation), mast cells
(antigen-presenting cells, osteoclast promoters, cytokine, and
histamine producers), and neutrophils (source of citrullinated
peptides, proteases, cytokines, and reactive oxygen species).
Metalloproteinases are also increased, alongside stimulators
of osteoclast activity, enhanced angiogenesis (with immature
blood vessels, expression of adhesion molecules in the vascular
endothelium, and formation of numerous endothelial venules),
lymphatic congestion, formation of ectopic lymphoid structures
(lymphoid aggregates with germinal centers), granulation tissue,
fibrin deposition, and fibrinoid necrosis in the sublining layer
(8, 10, 19, 21, 30, 33, 34).
Classification of Synovitis Based on
Immune Cell Analysis
Immunohistochemistry and immunofluorescence analyses
in early arthritis, to identify the dominant cells and the
inflammatory infiltrate intensity, allow classification of different
pathotypes, namely, the three synovial phenotypes: lympho-
myeloid, diffuse-myeloid, and pauci-immune/fibroid, each
one affecting about a third of patients (32, 35, 36). Cell types
analyzed include CD3+ (T cells), CD15+ (neutrophils), CD20+
CD22+ (B cells), CD21+ (dendritic follicular cells), CD31+ and
F VIII (endothelial vascular cells), CD38+ CD138+ (plasma
cells), CD45+ CD68+ CD163+ CD90− (macrophages), CD90+
CD45− CD55+ (fibroblasts), and CD117+ (mast cells). Biopsies
are stratified for each of these groups by semiquantitative
grading (0–4) of immunohistochemistry results revealing the
degree of immune cell infiltration, which is classified as follows:
lympho-myeloid, CD20+ cells ≥ 2 and/or CD138+ cells ≥
2; diffuse myeloid, sublining layer CD68+ cells ≥ 2, CD20+
cells ≤ 1, and/or CD3+ cells ≥ 1, and CD138+ cells ≤ 2; and
pauci-immune/fibroid, sublining layer CD68+ cells < 2 and
CD3+, CD20+, and CD 138+ cells < 1 (18, 32).
The lympho-myeloid pathotype is characterized by the
dominance of B cells and plasma cells, together with myeloid
cells, and can be associated with autoantibodies, osteoclast-
related genes, disease activity, structural damage, poor response
to csDMARDs, and good response to anti-IL 6 drugs. The
hallmark of the pauci-immune/fibroid pathotype is stroma-
resident cells, in association with scarce immune cells, low
levels of autoantibodies, lower activity, and less damage/disease
progression, but poor response to treatment. Themyeloid-diffuse
pathotype is characterized by the presence of myeloid cells and
scarce B cells, has intermediate features, relative to the two other
phenotypes, and may respond well to anti-TNF drugs (32, 35).
It has been postulated that, as the pauci-immune pathotype
occurs in a considerable proportion of cases of early arthritis,
this is a defined pathotype, rather than representing a burned-
out end-stage disease (35). Moreover, Lliso-Ribera et al. (36)
showed that synovial pathotypes can distinguish between clinical
phenotypes, independently of disease duration. Together, these
data question the dogma of the “opportunity window” in RA
treatment and demonstrate that patients with RA that fulfill
the 1987 ACR criteria have an increased probability of needing
biologic disease-modifying anti-rheumatic drugs (bDMARDs)
at some point during the disease course, relative to those
with undifferentiated arthritis or those that fulfill the 2010
ACR/EULAR criteria, but not the 1987 ACR criteria (36). Patients
needing bDMARDs exhibit upregulation of genes encoding
factors mediating the proliferation, differentiation, and activation
of B and T cells, and of matrix metallopeptidase production
and cytokine-mediated cell activation. Patients who do not
require bDMARDs mainly express genes regulating fibroblast
proliferation and cartilage turnover. Finally, the integration of
histologic and molecular signatures improves the sensitivity and
specificity of a model for predicting which patients would need
bDMARDs at some point during the disease course (36).
Regarding established RA, immunohistochemistry and
immunofluorescence can also identify several pathotypes, whose
various designations include diffuse, aggregate, lymphoid,
granulomatous, follicular, myeloid, fibroblastic, and pauci-
immune/fibroid synovitis (8, 37–39). Diffuse or myeloid
synovitis affects 50–70% of patients, is associated with good
responses to anti-TNF drugs, and has one of the most benign
clinical phenotypes, where rheumatoid factors tend to be absent,
CD68+ cells predominate, and there are few lymphocytes and
no ectopic lymphoid structures (39–41). Aggregate, follicular,
or lymphoid synovitis is associated with more active disease
and the presence of rheumatoid factor and tends to respond to
anti-IL6 drugs. It affects 22–50% of patients and may comprise
two subtypes, one associated with follicular dendritic cell
networks or ectopic/tertiary lymphoid-like structures, and
allegedly with worse outcome, and another which lacks those
networks/features (37–40). In follicular or lymphoid synovitis,
B cell infiltrates and B cell markers predominate, while pauci-
immune or fibroid synovitis is characterized by a fibroblast-rich
landscape, overexpression of cellular and molecular markers of
macrophages and fibroblasts, almost no immune cell infiltration,
no associated rheumatoid factor, and a poor response to anti-
TNF or anti-IL6 drugs (8, 39); this subtype affects 20–30%
of patients. Another much rarer pathotype, granulomatous
synovitis, affects < 1% of patients and is associated with extra-
articular features (38). Fibroblast-like synoviocytes with distinct
genetic signatures are also associated with different disease
phenotypes and outcomes (40); however, conflicting results have
been reported regarding the association of synovial lymphoid
aggregates and disease severity (41–44). Nevertheless, the overall
positive correlation between lymphoid aggregates and synovial
inflammation may simply be the result of interdependency,
rather than mutual exclusivity, between lymphoid and myeloid
infiltrates (41). It should also be stressed that synovitis scores
and pathotypes may vary among samples from the same
biopsy, because of minor differences between sections of the
same sample. Hence, final results should be defined only after
consideration of several samples and sections (37).
The existence of such diversified pathotypes indicates the
presence of distinct pathogenic pathways in the synovial
membrane and the need for therapeutic strategies directed
toward every scenario (17); however, some authors have
proposed that these data provide evidence of two main
pathogenic pathways, one through a lymphoid axis, targeted by
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drugs like tocilizumab, rituximab, and methotrexate, and another
through a myeloid axis, targeted by anti-TNF drugs (41).
Clinical Utility of Synovial Biopsies
Synovial Biopsy to Distinguish Synovitis Pathotypes
In a study conducted in the author’s department, the median
synovitis score was significantly superior in follicular pathotype
RA (5.8 ± 0.0), relative to the diffuse (4.0 ± 1.3) and
fibroid (2.5 ± 0.5) pathotypes. In the same study, the median
synovitis score was comparable between different inflammatory
rheumatic diseases but considerably superior to that in primarily
non-inflammatory conditions, such as osteoarthritis, synovial
chondromatosis, or foreign body synovitis (37). Comparison of
pathotypes among different rheumatic inflammatory conditions
did not reveal significant differences between various diagnoses,
except for a clear predominance of the diffuse pathotype in
spondylarthritis (SpA), the absence of the fibroid pathotype
in crystal-related arthropathies, and absence of the follicular
pathotype in primarily non-inflammatory arthritis (37).
Synovial membrane activation of JUN N-terminal kinase is
increased in early RA, but not in undifferentiated forms of
arthritis, and CD22+ and CD38+ cells distinguish RA from
other forms of arthritis (9). Compared with psoriatic arthritis
(PsA), RA synovial membranes contain fewer vessels, lower lipid
content, and fewer neutrophils, mast cells, CD163+, and CD117+
cells, with equal levels of lining and sublining CD68+ cells,
sublining CD3+, CD20+, and CD21+ cells, but higher levels of
CD138+ cells, and these differences appear to be independent
of therapy (26, 45, 46). DMARD-naïve PsA patients that had
reached minimum disease activity (MDA) at 6 months had lower
levels of CD3+ cells than those that did not reach MDA at 6
months. Similarly, naïve patients with RA that reached DAS28
remission at 6 months had lower levels of CD68+ cells than those
that did not reach remission at 6 months (45).
Patients with undifferentiated peripheral inflammatory
arthritis that evolved to a definite diagnosis had higher levels of
lining and sublining CD68+ and CD3+ cells than those who did
not evolve to a definite diagnosis. Similarly, patients with higher
grayscale ultrasound and power Doppler ultrasound scores were
more likely to evolve to a definite diagnosis than those who did
not (47).
Other features that may help to differentiate RA from SpA
and other diagnoses are the higher ratios of CD3+/CD4+ T cells,
RANKL/OPG, and CD20+/CD22+ B cells in the former. RA
patients also have more cell infiltration (B and T cells), more
lymphoid aggregates, and higher numbers of CD68+ sublining
macrophages and CD38+ plasma cells than those with SpA, but
lower M2 macrophage populations and, eventually, fewer blood
vessels in the sublining layer (21, 27, 34, 48, 49).
Quality and Quantity of Synovial Samples Collected
by USGSB
Humby et al. conducted a study in small joints of 35 patients
with RA, to determine whether USGSB at baseline and at
second biopsy could generate sufficient high-quality synovial
tissue for pathotype identification, RNA extraction, and detection
of sublining macrophage changes after treatment. They showed
that good-quality synovial tissue, adequately reflecting synovial
phenotype, was obtained in 81% of biopsies when synovial
hypertrophy > 2 was detected by grayscale ultrasound pre-
biopsy, opposed to 20% of those with a minimal degree of
synovial hypertrophy. In all biopsies, it was possible to retrieve
enough RNA for molecular analysis, regardless of pre-biopsy
synovial hypertrophy grade, as determined by ultrasound, and
a significant correlation was detected between the change in
the number of sublining CD68+ macrophages and treatment
response evaluated by DAS28. Moreover, they showed that
it was necessary to examine multiple biopsy samples, and
not only multiple sections of the same sample, to obtain a
representative image of the cell infiltrate; use of at least four
samples produced a good result, while examination of ≥10
samples (where possible) increased the percentage of evaluable
tissue substantially, in terms of CD3+, CD20+, and CD68+
cellular infiltrates. Further, they demonstrated that, in patients
with minimal synovial hypertrophy, increasing the number of
samples did not improve the quantity of gradable synovial tissue,
nor did the presence of Doppler signal predict the success of the
procedure (22).
Kelly et al. performed 93 synovial biopsies in large, as well as
small, joints, in patients with early RA, of which 36 had a second
biopsy 6 months later. A median of 14 samples was retrieved per
joint, and 93% of biopsies yielded good-quality synovial tissue,
which was maintained in even the second biopsy. RNA samples
extracted from all joints and all biopsies were adequate, even
those from repeat biopsies, although gradable tissue was only
obtained from 40% of small joints. The quantity and quality of
synovial tissue retrieved correlated with elevated synovitis score
determined by pre-biopsy ultrasound grayscale examination, but
not with power-Doppler grade. Self-limited joint discomfort,
solved in <24 h, was the most frequent adverse event, occurring
in 19% of patients (16).
Published data show that USGSB facilitates the collection
of synovial samples of sufficient quality in 82–96% of biopsies,
compared with 48–85% of blind needle biopsies (4–6, 32, 37,
50–52). Results are also influenced by operator expertise, joint
size and type, and synovitis grade, as determined by grayscale
ultrasound (6). In our department, of a series of 64 NB performed
in all kinds of joints, synovial bursae, and tendon sheaths,
81% were done within clinical practice to investigate a possible
infection, or to help to clarify a diagnosis, and 19% in the context
of research activities (37). Synovial biopsy had diagnostic and
treatment impact in 37% of cases and, in the research setting, 92%
of cases could be used for the proposed objectives. Of all biopsies,
88% yielded synovial tissue, consistent with literature reports
(4, 37). Notably, the median sample number was significantly
lower in biopsies from which synovium was not successfully
retrieved and, of eight unsuccessful biopsies, six were from large
joints. Operator experience also had a clear impact on the quality
of synovial tissue obtained (37). Remarkably, synovial tissue was
less likely to be successfully obtained from samples collected
later in the procedure and had fewer concordant pathotypes than
those collected early. Consequently, the authors recommend that
samples collected for different purposes should be assigned in
parallel, rather than sequentially (37).
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Synovial Biopsy to Evaluate Disease Progression and
Treatment Response
Alivernini et al. used ultrasound and synovial
immunohistochemistry to study 42 patients with undifferentiated
peripheral arthritis with rheumatoid factor, who were anti-
citrullinated protein antibodies (ACPA) negative and naïve to
DMARDs. They found a correlation between CD68+ lining
and sublining layer cells and CD 31+ (intravascular) cells and
ultrasound scores. The few patients that evolved to a definite
diagnosis had significantly higher levels of the aforementioned
cells and higher ultrasound scores and CD3+ cell numbers in the
sublining layer. These patients also exhibited downregulation of
miRNAs 346 and 214 (47).
Just et al. conducted baseline and 6-month ultrasound,
magnetic resonance imaging (MRI), and synovial biopsy
assessments in 20 patients with early RA and 20 with established
RA. They found that EULAR-OMERACT ultrasound score
and RAMRIS MRI score were strongly correlated with Krenn’s
synovitis score at baseline, but not 6-month assessment, in
the early RA group. In the established RA group, a moderate
to strong correlation was present between the three scores
at baseline assessment, except for the RAMRIS 6-month
assessment, which was not performed (53).
Rivellese et al. detected CD20+ cell infiltrate ≥ 2 (0–4) and
B-cell-rich synovitis in 35% of DMARDs-naïve early RA and
47.7% of established RA, with inadequate responses to anti-
TNF, which were significant differences. They also found that
patients with B-cell-rich synovitis had higher levels of disease
activity, rheumatoid factor, and ACPA positivity, but only in early
RA, not established RA. Nevertheless, patients with both early
and established RA with B-cell synovitis also had higher total
histologic synovitis scores. According to the authors, this lack
of correlation between B-cell-rich synovitis and clinical disease
activity scores (DAS28) could be a sign of the insensitivity of
clinical scores for capturing synovial inflammation and may
explain the progressive structural damage in patients with low
clinical disease activity (54).
Two independent groups compared ACPA-positive and
-negative patients with established RA and found that
synovial numbers of CD3+, CD8+, CD19+, and B cells
were significantly higher in ACPA-positive patients; however,
they also had more active disease, introducing bias in the analysis
(55, 56).
After 3 months of treatment with tocilizumab, a marked
decrease in CD3+ cells was detected in patients with early RA
(57). After 3 months of treatment with adalimumab, patients
with RA and an inadequate response to methotrexate had a
marked decrease in CD 68+ cells (58). Finally, 3 months of
treatment with rituximab resulted in a significant reduction
in both B cells and IL-17-producing T cells in patients with
RA (59).
The R4RA study investigated the best therapeutic option
between rituximab vs. tocilizumab for patients with RA and
previous inadequate response to anti-TNF, by assessing whether
molecular and cellular signatures of B cells predicted a better
response to rituximab. Tocilizumab showed better results in the
B cell-poor group and was not inferior to rituximab in the B
cell-rich group, although there was a higher incidence of adverse
events (60).
Diagnostic Value of USGSB
In RA, there is a tendency to find similar numbers of cells in
the sublining layers of different joints in the same patient, even
between clinically involved and non-involved joints, although
less pronounced in clinically uninvolved joints; however, this
does not occur in the synovial lining layer, in which there are
no similarities in the number or characteristics of macrophages
and fibroblast-like synoviocytes between clinically involved
and non-involved joints, with distinctive DNA fingerprints
and methylation patterns, according to their positional
memory (9).
In septic arthritis, compared with synovial fluid analysis,
USGSB increased the percentage of causative agent isolation in
non-specific infections, as well as mycobacterial infections (6).
Perivascular infiltrate of neutrophils, which typically comprise
> 20% of all cells in synovial tissue of septic arthritis, as well as
polymerase chain reaction for identification of bacteria and fungi,
have remarkably high sensitivity and specificity for detecting
the presence of infection. In addition to infectious arthritis,
there are several other situations in which synovial biopsy may
be diagnostic, including Whipple and Wilson diseases, synovial
chondromatosis, pigmented villonodular synovitis, ochronosis,
synovial lipoma arborescens, foreign body synovitis, crystal-
related arthropathies, amyloidosis, hemochromatosis, histiocytic
and neoplastic diseases, and sarcoidosis (6).
Adverse Events Related to USGSB
Adverse events are uncommon in USGSB and usually mild and
transient; however, adverse event rates < 0.5%, as described in
some series, seem unrealistic and likely reflect a low-sensitivity
data collection strategy (3, 5, 7). Reported adverse events include
vasovagal reaction; sensory disturbance; nerve, vessel, tendon,
ligament, or muscle lesion; ecchymosis, hemarthrosis, skin, or
joint infection; sinus tract from joint to skin; fracture of biopsy
needle; and thrombophlebitis or deep venous thrombosis (11, 16,
22, 61). Transient post-procedure sensory disturbance, vasovagal
reaction (1–2% of cases) and joint discomfort post-biopsy
(usually < 24 h; 7–19% of cases) are the most reported adverse
events (5, 10, 16, 37). In a series of 524 synovial biopsies (402
NB, 65 PFB, and 57 arthroscopic), adverse events were detected
in 1.5% of procedures, with no difference among methods. All
patients reported clear improvement 2 weeks post-procedure.
Repeated biopsies did not increase the number of adverse events
or patient-reported outcomes (3). In our series, adverse events
were considered discreet and transient, except for a single case of
a slight limitation of fifth finger extension, which persisted after a
wrist biopsy (37).
DISCUSSION
What Are the Unmet Needs Related to
Synovial Biopsy?
Our capacity to induce sustained remission or cure of RA and
other inflammatory arthritis at the individual level remains
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BOX 1 | Unmet needs related to USGSB and synovial tissue analysis.
General Framework:
More robust validation in multiple centers
Compare the procedure, performance, and safety of PFB and NB
appropriately, to produce a consensual definition of a successful procedure
Define training goals for practitioners learning how to perform USGSB
Specific Technical Issues:
Standardize sample acquisition (number of samples according to goals,
define sites within the joint), processing, analysis, and reporting of results
Pathotype:
• How tomanage dynamic changes in pathotype that occur over the disease
course and after treatment
• How many observations are required to define the dominant pathotype,
since it may change according to the harvesting sequence, across
samples from the same joint, and across joints from the same patient
Define the best cutoff to differentiate pathotypes that share overlapping
features.
Main Technical Goals:
Identification of synovial biomarkers that distinguish between different types
of arthritis and other diseases
Determine if synovial histopathological heterogeneity translates into diverse
clinical phenotypes
Determine if it is an adequate method for patient stratification and treatment
monitoring
Search for molecular signatures modulated by specific therapeutic
approaches
Determine whether synovial biopsies early in the disease course can predict
outcomes and identify patients that will respond to bDMARDs/csDMARDs
and those who will not
limited, due to insufficient information to drive treatment.
As synovitis is the hallmark of these diseases, accessing the
core site of the pathological process (synovial tissue) provides
opportunities to gather information with potential diagnostic and
prognostic utility. Synovial tissue biomarkers appear an attractive
target for that purpose, due to the inadequacy of peripheral blood
biomarkers. An equivalent path has been followed in oncology,
where histopathology has demonstrated prognostic value and is
now integrated into the standard of care (15).
Several unmet needs related to USGSB and synovial tissue
analysis remain a challenge for those working in the field of
rheumatology, as outlined in Box 1. The ultimate goal is to find
the ideal treatment, in the right time frame for each patient, using
a precision medicine approach, as applied in cancer therapy. We
believe that analysis of synovial tissue will play a decisive role in
this strategy, hopefully in the near future (5, 15, 40).
The absence of robust, predictive biomarkers of treatment
outcomes is a major unmet need in the management of RA and
other types of inflammatory arthritis. A precise understanding
of the key events occurring during synovitis will be critical
in advancing the era of precision medicine in RA and other
inflammatory rheumatic diseases, placing synovial tissue analysis
at the core of this journey. However, before proposing routine use
of standardized synovial tissue biopsy to guide therapy, several
factors must be satisfied, according to the OMERACT Synovial
Tissue Biopsy Special Interest Group, including uniformity
of biopsy handling and analysis, validation of quality scores,
and relationship between immunopathology and therapeutic
response and between disease pathotypes and outcomes (62).
Conclusion
In conclusion, available data demonstrate that USGSB is an
effective, safe, and well-tolerated method of retrieving quality
synovial tissue from any type of joint, with impacts on diagnosis
and treatment. In the clinical setting, formal indication for
synovial biopsy occurs mainly in monoarthritis cases, to exclude
infection, and although synovial biopsy still cannot be used to
distinguish between types of inflammatory rheumatic diseases,
it has led to remarkable advances in the understanding of the
pathobiology of RA and other inflammatory rheumatic diseases.
Histopathological analysis, immunohistochemistry, and omic
and molecular analyses of synovial tissue have brought us to the
cusp of an era of personalized medicine in rheumatology.
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